Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Bearish flow noted in Gilead (GILD) with 1,949 puts trading, or 1.3x expected. Most active are 4/4 weekly 107 puts and Apr-25 109 puts, with ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...

Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

Google’s $32B Wiz acquisition raises questions on strategy, AI competition, and cloud dominance as investors react ...

ROCKVILLE, MD, USA I March 20, 2025 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and ...

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...